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Theoretical and empirical work over the past several decades suggests that oncogenesis
and disease progression represents an evolutionary story. Despite this knowledge,
current anti-resistance strategies to drugs are often managed through treating cancers
as independent biological agents divorced from human activity. Yet once drug resistance
to cancer treatment is understood as a product of artificial or anthropogenic rather
than unconscious selection, oncologists could improve outcomes for their patients by
consulting evolutionary studies of oncology prior to clinical trial and treatment plan design.
In the setting of multiple cancer types, for example, a machine learning algorithm can
predict the genetic changes known to be related to drug resistance. In this way, a unity
between technology and theory might have practical clinical implications—and may pave
the way for a new paradigm shift in medicine.
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A PARADIGM SHIFT IN ONCOLOGY
Evolutionary theory is becoming increasingly prominent in traditional medical practice, and
oncology is no exception. Researchers across disciplines are improving the understanding of cancer
from both the theoretical and treatment-oriented perspectives, with, as has been shown in the first
studies of their kind, better outcomes in the clinical trials developed from an evolutionary point
of view.
Perspectives from natural selection are, perhaps foremost, helping to clarify what cancer actually
is. Mazzocca recently proposed a “systemic-evolutionary theory of cancer,” which treats cancer as
a regression from multicellularity to the sub-systemic level (1, 2). Fais and Fauvarque argued that
cancer cells should actually be viewed as unicellular organisms—divorced from the larger biological
system altogether (3). Another position is that cancer should be treated as the result of the lifting of
the evolutionary imposed barriers—for example, programmed cell death—that help the human
body to prevent oncogenesis and cancer proliferation; in this sense they are understood as the
“inevitable cheaters” that succeed in the absence of defenses against them (4).
General theories of the evolution of cancer are, furthermore, making it clear how critical
understanding the tumor microenvironment, from the viewpoint of natural and artificial selection,
is when attempting to predict how tumors are likely to grow independently or in the presence
of anticancer treatment. Gillies et al., for example, proposed in 2018 that cancer cells should be
considered independent targets of selection, which evolve only in response to factors affecting the
immediate microenvironment (5).
Goodman and Ashrafian Evolution and AI in Oncology
As a uniquely predictive theoretical science, evolutionary
biology is, furthermore, starting to affect how clinically
devastating phenomena, such as drug resistance, are understood.
Intratumoural genomic heterogeneity is, for example, a now-
established evolutionary factor involved in the evolution of drug
resistance (6, 7). If a small number of cells carry inherent
resistance to a targeted therapy or chemotherapy, resistant clones
will continue to multiply as non-resistant cells are selected
against; this process is known in ecology as competitive release
(8). One possibility to overcome resistance is therefore to target
therapy not only against particular mutations, but through
stratification based on inherent resistance detected within a
particular tumor (9).
Yet while heterogeneity may be one driver of drug
resistance, tumors are able to evade targeted treatments and
immunotherapies via other mechanisms, including increased
numbers of regulatory T cells and myeloid suppressor cells
in the tumor microenvironment, abnormal vascularization,
and the formation of cancer-associated fibroblasts (10–14).
Immunotherapies including vaccines or checkpoint inhibitors
are also less effective in settings where tumors are large
or metastatic: immunosuppressive signals expressed by cells
within the tumor microenvironment preclude long-term survival
improvements for patients, particularly if an immunotherapy is
used as a monotherapy (15). Targeted therapies, such as BRAF
inhibitors for melanoma, are also rendered ineffective if cancer
cells proliferate via other mechanisms, for example secondary
BRAFV600 mutations, N-RAS upregulation, and activation of
survival pathways via tyrosine kinase receptor–mediation (16,
17). Gopal et al. recently showed, however, that tumor sweep
dynamics affect responses to anti-BRAF/MEK therapy; the
resulting clonal evolutionary dynamics may help to design more
effective therapeutic regimens (18).
There are numerous other examples of recent or ongoing
studies that could be clarified by understanding how cancer
evolves: resistant clones are favored when treatment-sensitive
cells are selected against. Advanced or metastatic tumors can
suppress the immune system in a variety of ways. Other therapies
that inhibit protein or chemical production select for alternate
pathways of tumor proliferation: in prostate cancer, for example,
intratumoural synthesis of androgen is suggested as a mechanism
among chemically castrated patients (19). Below we highlight
several models and trials that have and are changing oncology
into a more evolutionarily focused discipline, and suggest that a
unity of data science with evolutionary theory will be necessary
for true clinical improvements across oncology.
EVOLUTIONARY MODELS AND STUDIES
Mathematical Models
Outside of oncology, evolutionarily informed modeling has been
fundamental for predicting and preventing antibiotic resistance.
Nichol et al. show, for example, using a Markov chain model
that antibiotics can, depending on the drug’s sequence, promote
or prevent antibiotic resistance in Escherichia coli (20). The
authors use the model to show how drug sequence can act as an
evolutionary “steering” mechanism.
Within oncology, a number of mathematical models have
been used to predict cancer cell proliferation, metastasis, and
the evolution of drug resistance. Zhao et al. recently reviewed
a number of models that may help to predict oncogenesis,
heterogeneity within tumors, metastasis, and drug resistance,
some of which have been studied for almost 50 years (21). In the
1970s, Norton and Simon, for example, argued using a Gompertz
function that drug and radiotherapy cycles should be as close
together as possible to maximize tumor shrinkage (22, 23).
Two modeled strategies have, in particular, been closely
studied: evolutionary traps and temporal collateral sensitivity,
both of which may function as steering mechanisms for clinical
oncologists. Temporal collateral sensitivity involves mapping
a tumor’s evolutionary trajectory during treatment in case
sensitivity to a second drug is promoted (24, 25). An evolutionary
trap, on the other hand, involves targeting a particular cell
population within tumors to sensitize the cancer to a second drug
(26). Preclinical models and clinical studies suggest that, at the
very least, the latter approach can improve overall response rates
in cancer patients.
Preclinical Models
Evolutionarily informed in vitro, in vivo, and murine models
show promising results for managing drug resistance in
the clinical setting. In a preclinical study of the temporal
collateral sensitivity study, Zhao et al. showed, for example,
that Philadelphia chromosome–positive acute lymphoblastic
leukemia can be sensitized to non-classical BCR-ABL1 inhibitors
as the disease evolves resistance to classical BCR-ABL1
inhibitors (25).
Another strategy, “adaptive therapy,” is not designed to
maximize tumor cell death, but rather to kill only so many
sensitive cells so as to maintain intertumoural competition
between sensitive and resistant cells (27). This strategy may
prevent competitive release, improving survival, and quality of
life among patients with incurable cancer. Preclinical studies
suggest that intermittent dosing may successfully implement this
idea (28, 29).
Clinical Studies
Several clinical studies that rely on evolutionary modeling have
met with some success. The adaptive therapy model, which has
been attempted in prostate cancer, led to improved progression-
free and overall survival rates among patients with metastatic
disease (30). The researchers used Lotka-Volterra equations to
develop an adaptive model for abiraterone acetate use in prostate
cancer; in a phase 1 trial, about half the standard abiraterone
dosage was used as adaptive therapy, while progression-free
survival was improved by more than 10 months (median 27 vs.
16.5 months in historical controls).
Another evolutionarily informed strategy, double-bind
therapy (an evolutionary trap), was used by Antonia et al. to
induce a 67% chemotherapy response rate in patients with
small-cell lung cancer, compared with <5% in historical controls
(31). Twenty-nine patients were given an anti-p53 vaccine prior
to chemotherapy, which, evolutionarily speaking, primed the
cancers to respond to cytotoxic therapy.
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Yet despite these remarkable clinical and mathematical
achievements, we are still unable to predict, enmasse, exactly how
specific cancers will evolve to promote drug resistance—we seem
to still almost always be one step behind a tumor’s evolutionary
trajectory. Predicting the evolutionary story is theoretically
possible given our understanding of cancer progression—but we
lack the ability, as of yet, to make accurate predictions of tumor
growth rates, locations, and disease spread. As a result, many
treatment strategies are reactive rather than proactive to disease
processes; such that clinicians often find themselves “on the back
foot” with regard to anti-cancer management.
One study, TRACERx, was, however, developed to track the
evolution of non-small-cell lung cancer at the molecular level as
tumors grow, metastasize, and are effectively (or ineffectively)
treated (32). The goal is to develop a dataset of genetic changes
large enough to guide treatment for particular patients no matter
the disease stage at diagnosis. In 2017, furthermore, Maley et al.
proposed an evolutionary and ecological framework classifying
tumors (33). The framework is intended, in the long term, to help
clinicians choose and time treatments effectively as neoplasms
evolve naturally and in response to interventions.
UNITING EVOLUTIONARY MEDICINE AND
DATA SCIENCE
While the aforementioned studies are each an important step
in developing a narrative of how cancer evolves, several
shortcomings exist, as there are seemingly infinite number
of relationships among the genes, proteins, and pathways
integral to oncogenesis and disease progression. Tracking
disease development is also only one part of the solution: to
effectively choose and time treatment, we need to be able predict
evolutionary change in every neoplasm.
Machine learning may help us move forward. A 2018
paper by Caravagna et al. showed that a transfer learning
approach—dubbed, in this case “repeated evolution in cancer
(REVOLVER)”—can effectively analyse multi-region sequencing
data to parse evolutionary steps in cancer progression that might
have otherwise been overlooked by human observers (34). The
trajectories mapped through the machine learning algorithm
made anticipation of progression possible for other reviewed
samples. Specifically, the field of evolutionary algorithms with
refinedmathematical prediction and optimization capability may
prove to offer particularly strong advantages here.
These results suggest that machine learning may be the
missing piece in the evolutionary story of cancer progression.
Coupled with evolutionary logic, machine learning is likely
the only way, given our current understanding of genetics,
to effectively predict disease progression in the absence of,
or with, human interventions. If the tenets of evolutionary
theory continue to be integrated into digital tools of oncology
therapeutics, then subsequent treatment may be timed and dosed
to provide the maximum clinical benefit to the patient while
minimizing toxic events. In this way the digital revolution and
theoretical biology can be unified to improve the quality of
clinical care and cancer outcomes.
DATA AVAILABILITY STATEMENT
All datasets for this study are included in the
article/supplementary material.
AUTHOR CONTRIBUTIONS
JG wrote the initial manuscript. HA made significant edits and
changes, and added some new thoughts.
REFERENCES
1. Mazzocca A. The systemic–evolutionary theory of the origin of cancer
(SETOC): a new interpretativemodel of cancer as a complex biological system.
Int J Mol Sci. (2019) 20:E4885. doi: 10.3390/ijms20194885
2. Mazzocca A, Ferraro G, Misciagna G, Fais S. Moving the systemic
evolutionary approach to cancer forward: therapeutic implications. Med
Hypotheses. (2018) 121:80–7. doi: 10.1016/j.mehy.2018.09.033
3. Fais S, FauvarqueMO. TM9 and cannibalism: how to learn more about cancer
by studying amoebae and invertebrates. Trends Mol Med. (2012) 18:4–5.
doi: 10.1016/j.molmed.2011.09.001
4. Ewald PW, Swain Ewald HA. Toward a general evolutionary theory of
oncogenesis. Evol Appl. (2013) 6:70–81. doi: 10.1111/eva.12023
5. Gillies RJ, Brown JS, Anderson ARA, Gatenby RA. Eco-evolutionary causes
and consequences of temporal changes in intratumoural blood flow. Nat Rev
Cancer. (2018) 18:576–85. doi: 10.1038/s41568-018-0030-7
6. Dey N, Williams C, Leyland-Jones B, De P. Mutation matters in precision
medicine: a future to believe in. Cancer Treat Rev. (2017) 55:136–49.
doi: 10.1016/j.ctrv.2017.03.002
7. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis
and why targeted therapy does not work. Nat Rev Cancer. (2012) 12:487–93.
doi: 10.1038/nrc3298
8. Connell JH. The influence of interspecific competition and other
factors on the distribution of the barnacle Chthamalus stellatus. Ecology.
(1961) 42:710–23.
9. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance
mutations on targeted cancer therapy. Nat Rev Clin Oncol. (2016) 13:335–47.
doi: 10.1038/nrclinonc.2015.175
10. Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler
C, et al. Rare cell variability and drug-induced reprogramming
as a mode of cancer drug resistance. Nature. (2017) 546:
431–35. doi: 10.1038/nature22794
11. Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced
stemness in tumour relapse: ‘what does not kill me strengthens me’. Br J
Cancer. (2015) 112:1725–32. doi: 10.1038/bjc.2015.146
12. Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C. Eradication of
large tumors in mice by a tritherapy targeting the innate, adaptive, and
regulatory components of the immune system.Cancer Res. (2007) 67:8847–55.
doi: 10.1158/0008-5472.CAN-07-0321
13. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose
irradiation programs macrophage differentiation to an iNOS?/M1 phenotype
that orchestrates effective T cell immunotherapy. Cancer Cell. (2013) 24:589–
602. doi: 10.1016/j.ccr.2013.09.014
14. Sharma SH, Thulasingam S, Nagarajan S. Chemopreventive agents
targeting tumor microenvironment. Life Sci. (2016) 145:74–84.
doi: 10.1016/j.lfs.2015.12.016
15. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.
Vaccines for established cancer: overcoming the challenges posed by
immune evasion. Nat Rev Cancer. (2016) 16:219–33. doi: 10.1038/nrc.2
016.16
Frontiers in Oncology | www.frontiersin.org 3 January 2020 | Volume 9 | Article 1527
Goodman and Ashrafian Evolution and AI in Oncology
16. Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF
and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer.
(2016) 62:76–85. doi: 10.1016/j.ejca.2016.04.005
17. Nazarian R, Shi H, Wang Q. Melanomas acquire resistance to B-RAF(V600E)
inhibition by RTK or N-RAS upregulation. Nature. (2010) 468:973–77.
doi: 10.1038/nature09626
18. Gopal P, Sarihan EI, Chie EK, Kuzmishin G, Doken S, Pennell NA, et al. Clonal
selection confers distinct evolutionary trajectories in BRAF-driven cancers.
Nat Comm. (2019) 10:5143. doi: 10.1038/s41467-019-13161-x
19. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer
pathogenesis and response to therapy. Endocr Relat Cancer. (2011) 18:R175–
82. doi: 10.1530/ERC-10-0339
20. Nichol D, Jeavons P, Fletcher AG, Bonomo RA, Maini PK, Paul JL,
et al. Steering evolution with sequential therapy to prevent the emergence
of bacterial antibiotic resistance. PLoS Comput Biol. (2015) 11:e1004493.
doi: 10.1371/journal.pcbi.1004493
21. Zhao B, Hemann MT, Lauffenburger DA. Modeling tumor clonal
evolution for drug combinations design. Trends Cancer. (2016) 2:144–58.
doi: 10.1016/j.trecan.2016.02.001
22. Norton L, Simon R. Growth curve of an experimental solid tumor following
radiotherapy. J Natl Cancer Inst. (1977) 58:1735–41.
23. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment
schedules. Cancer Treat Rep. (1977) 61:1307–17.
24. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-
resistance and collateral sensitivity in seven resistant small-cell lung cancer
cell lines: preclinical identification of suitable drug partners to taxotere, taxol,
topotecan and gemcitabin. Br J Cancer. (1997) 75:869–77.
25. Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, et al. Exploiting
temporal collateral sensitivity in tumor clonal evolution. Cell. (2016) 165:234–
46. doi: 10.1016/j.cell.2016.01.045
26. Chen G, Mulla WA, Kucharavy A, Tsai HJ, Rubinstein B, Conkright J,
et al. Targeting the adaptability of heterogeneous aneuploids. Cell. (2015)
160:771–84. doi: 10.1016/j.cell.2015.01.026
27. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res.
(2009) 69:4894–903. doi: 10.1158/0008-5472.CAN-08-3658
28. Kam Y, Das T, Tian H, Foroutan P, Ruiz E, Martinez G, et al. Sweat
but no gain: inhibiting proliferation of multidrug resistant cancer cells
with “Ersatzdroges.” Int J Cancer. (2015) 136:E188–96. doi: 10.1002/ijc.
29158
29. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary
approaches to prolong progression-free survival in breast cancer. Cancer Res.
(2012) 72:6362–70. doi: 10.1158/0008-5472.CAN-12-2235
30. Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary
dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat
Commun. (2017) 8:1816. doi: 10.1038/s41467-017-01968-5
31. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N,
et al. Combination of p53 cancer vaccine with chemotherapy in patients
with extensive stage small cell lung cancer. Clin Cancer Res. (2006) 12(3 Pt
1):878–87. doi: 10.1158/1078-0432.CCR-05-2013
32. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK,
Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl
J Med. (2017) 376:2109–21. doi: 10.1056/NEJMoa1616288
33. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M,
et al. Classifying the evolutionary and ecological features of neoplasms. Nat
Rev Cancer. (2017) 17:605–19. doi: 10.1038/nrc.2017.69
34. Caravagna G, Giarratano Y, Ramazzotti D, Tomlinson I, Graham
TA, Sanguinetti G, et al. Detecting repeated cancer evolution from
multi-region tumor sequencing data. Nat Methods. (2018) 15:707–14.
doi: 10.1038/s41592-018-0108-x
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Goodman and Ashrafian. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org 4 January 2020 | Volume 9 | Article 1527
